Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.

Rhea-AI Summary

Lakeside Holding (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider, has acquired Hupan Pharmaceutical (Hubei) Co., through its subsidiary Sichuan Hupan Jincheng Enterprise Management Co., The acquisition, valued at RMB 4.0 million (US$0.6 million), is expected to add approximately US$7 million in annual revenue to Lakeside. Hupan Pharmaceutical, founded in May 2024 and headquartered in Wuhan, specializes in pharmaceutical distribution and supply chain services, including refrigerated and frozen pharmaceuticals, peptide hormones, and other critical medications. The company holds licenses for drug wholesale, retail, and third-class medical device distribution in China. Hupan Pharmaceutical has partnerships with leading pharmaceutical manufacturers and regional healthcare institutions, including 15 major hospitals in Wuhan. This acquisition strengthens Lakeside's capabilities in the medical logistics sector in China.

Positive

• The acquisition is expected to add approximately US$7 million in annual revenue.
• Lakeside gains entry into the lucrative medical logistics sector.
• Hupan Pharmaceutical has established partnerships with leading pharmaceutical manufacturers and healthcare institutions in Wuhan.

Negative

• The acquisition cost of RMB 4.0 million (US$0.6 million) could impact Lakeside's short-term financials.

Insights

Financial Analyst

This strategic acquisition marks a significant pivot into China's pharmaceutical logistics sector with compelling financial metrics. The $0.6 million purchase price appears notably modest compared to the projected $7 million in annual revenue contribution, suggesting an attractive price-to-sales multiple of just 0.09x. For a micro-cap company with an $18.9 million market cap, this revenue addition could be transformative, potentially increasing total revenues by a material percentage.

The partnership with Sinopharm Group, ranked 24th in Fortune China 500, provides substantial credibility and growth potential. The deal structure through Sichuan Hupan demonstrates careful consideration of Chinese regulatory requirements. Key value drivers include existing relationships with 15 major hospitals and specialized capabilities in high-value segments like oncology and aesthetic medicine.

Supply Chain Expert

The acquisition strategically positions Lakeside in China's specialized pharmaceutical cold chain market - a high-barrier-to-entry segment requiring strict compliance and specialized infrastructure. Hupan Pharmaceutical's licenses for drug wholesale, retail and third-class medical devices, plus capabilities in temperature-controlled logistics for sensitive products like peptide hormones, represent significant regulatory and operational advantages that would take years to develop organically.

The Wuhan location is particularly strategic, serving as a major transportation hub in central China. The established relationship with Sinopharm, China's leading pharmaceutical distributor, provides a strong foundation for expansion beyond the current 15-hospital network.

Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue

ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand American Bear Logistics (ABL), is pleased to announce that through its wholly-owned subsidiary Sichuan Hupan Jincheng Enterprise Management Co., Ltd. ("Sichuan Hupan"), has entered into an equity transfer agreement to acquire Hupan Pharmaceutical (Hubei) Co., Ltd. ("Hupan Pharmaceutical"), gaining entry into the medical logistics sector. The acquisition, valued at RMB 4.0 million (US$0.6 million), is anticipated to deliver approximately US$7 million of annual revenues to Lakeside.

Founded in May 2024 and headquartered in Wuhan, Hupan Pharmaceutical is a comprehensive pharmaceutical distribution and supply chain service provider with verticals in brand promotion and healthcare technology support. Hupan Pharmaceutical is licensed for drug wholesale, retail, and third-class medical device distribution in China, with recent expansion to include refrigerated and frozen pharmaceuticals, peptide hormones, and other critical medications.

Hupan Pharmaceutical has partnerships with leading pharmaceutical manufacturers, regional healthcare institutions, and 15 major hospitals in Wuhan, including the Sinopharm Group Hubei Co., Ltd. The Sinopharm Group Hubei Co., Ltd. is the subsidiary of Sinopharm Group Co., Ltd.(Sinopharm Holding). Sinopharm Holding a top player in China's pharmaceutical industry, ranked 24th in the 2022 Fortune China 500 and first among pharmaceutical companies. It is recognized as a "2022 National Demonstration Enterprise for Supply Chain Innovation and Application" and among the top 100 most valuable Chinese brands.With an MSCI ESG rating of A, Sinopharm Holding is an industry leader in corporate responsibility and supply chain stability.

Known for its extensive clinical supply expertise in oncology, antibiotics, large-volume infusions, and aesthetic medicine, Hupan Pharmaceutical is well-positioned to meet the needs of a broad range of healthcare institutions across Hubei.

"The acquisition of Hupan Pharmaceutical provides Lakeside with an important foothold into the lucrative medical logistics trade," said Henry Liu, Chairman & CEO of Lakeside. "With American Bear Logistics and now Hupan Pharmaceutical, Lakeside is positioned with two highly specialized companies, each supported by experienced teams, advanced technology, and a solid foundation of customer trust. This acquisition enables us to bring top-tier logistics and supply chain solutions to the pharmaceutical sector in China, expanding our reach and capabilities across critical and emerging markets."

About Lakeside Holding Limited

Lakeside Holding Limited, based in Itasca, IL, is a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market, including China and South Korea. Operating under the brand American Bear Logistics, we primarily provide customized cross-border ocean freight solutions and airfreight solutions in the U.S. that specifically cater to our customers' requirements and needs in transporting goods into the U.S. We are an Asian American-owned business rooted in the U.S. with in-depth understanding of both the U.S. and Asian international trading and logistics service markets. Our customers are typically Asia- and U.S.-based logistics service companies serving large e-commerce platforms, social commerce platforms, and manufacturers to sell and transport consumer and industrial goods made in Asia into the U.S. For more information, please visit https://lakeside-holding.com.  

Safe Harbor Statement

This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors  may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com 

View original content:https://www.prnewswire.com/news-releases/lakeside-holding-enters-medical-logistics-sector-with-acquisition-of-hupan-pharmaceutical-hubei-co-ltd-302300792.html

SOURCE Lakeside Holding Limited

FAQ

What is the value of Lakeside Holding's acquisition of Hupan Pharmaceutical?

The acquisition is valued at RMB 4.0 million (US$0.6 million).

How much annual revenue is expected from the acquisition of Hupan Pharmaceutical?

The acquisition is projected to add approximately US$7 million in annual revenue.

What sector does Lakeside Holding enter with the acquisition of Hupan Pharmaceutical?

Lakeside Holding enters the medical logistics sector with this acquisition.

Who are some of Hupan Pharmaceutical's partners in the healthcare sector?

Hupan Pharmaceutical has partnerships with leading pharmaceutical manufacturers and 15 major hospitals in Wuhan.

What licenses does Hupan Pharmaceutical hold?

Hupan Pharmaceutical holds licenses for drug wholesale, retail, and third-class medical device distribution in China.